Terpos E, et al. - Among transplant-eligible newly diagnosed multiple myeloma (NDMM) patients enrolled in this Phase 2 study, researchers assessed lenalidomide, adriamycin and dexamethasone (RAD) regimen for its efficacy and safety as induction, as well as its impacts on bone metabolism and angiogenesis. A 66.7% overall response rate was reported after four cycles of RAD. A favorable toxicity profile was displayed. Bone resorption markers CTX and TRACP-5b were significantly attenuated by RAD. Bone formation markers bone-specific alkaline phosphatase, procollagen type 1 amino-terminal propeptide and osteocalcin were increased with RAD. Beneficial impacts of RAD on bone metabolism and angiogenesis were evident and RAD proved effective as induction regimen prior to autologous stem cell transplantation.